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Abstract
Background: Community-acquired pneumonia (CAP) remains a major cause of morbidity and
mortality throughout the world. Telithromycin (a new ketolide) has shown good in vitro activity
against the key causative pathogens of CAP, including S pneumoniae resistant to penicillin and/or
macrolides.
Methods: The efficacy and safety of telithromycin 800 mg orally once daily for 7 days in the
treatment of CAP were assessed in an open-label, multicenter study of 442 adults.
Results:  Of 149 microbiologically evaluable patients, 57 (9 bacteremic) had Streptococcus
pneumoniae. Of the 57 S pneumoniae pathogens isolated in these patients, 9 (2 bacteremic) were
penicillin- or erythromycin-resistant; all 57 were susceptible to telithromycin and were eradicated.
Other pathogens and their eradication rates were: Haemophilus influenzae (96%),  Moraxella
catarrhalis (100%), Staphylococcus aureus (80%), and Legionella spp. (100%). The overall bacteriologic
eradication rate was 91.9%. Of the 357 clinically evaluable patients, clinical cure was achieved in
332 (93%). In the 430 patients evaluable for safety, the most common drug-related adverse events
were diarrhea (8.1%) and nausea (5.8%).
Conclusion: Telithromycin 800 mg once daily for 7 days is an effective and well-tolerated oral
monotherapy and offers a new treatment option for CAP patients, including those with resistant S
pneumoniae.
Background
Community-acquired pneumonia (CAP) remains a major
cause of morbidity and mortality throughout the world.
In the USA alone, an estimated 3–4 million cases of CAP
account for approximately 10 million physician visits,
500,000 hospitalizations, and 45,000 deaths each year
[1,2]. Common bacterial pathogens in CAP include Strep-
tococcus pneumoniae,  Haemophilus influenzae,  Moraxella
catarrhalis,  Mycoplasma pneumoniae,  Chlamydia pneumo-
niae, and Legionella pneumophila. Ideally, antibiotic ther-
apy for CAP should be based on etiologic diagnosis. The
Infectious Diseases Society of America (IDSA) recom-
mends microbiologic testing, including sputum and
blood cultures, in hospitalized CAP patients, and encour-
ages sputum culture and Gram staining in CAP outpa-
tients [2]. Practically, however, microbiologic test results
Published: 31 May 2005
BMC Infectious Diseases 2005, 5:43 doi:10.1186/1471-2334-5-43
Received: 18 August 2004
Accepted: 31 May 2005
This article is available from: http://www.biomedcentral.com/1471-2334/5/43
© 2005 Fogarty et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2005, 5:43 http://www.biomedcentral.com/1471-2334/5/43
Page 2 of 9
(page number not for citation purposes)
are not usually immediately available and a clinician
needs to initiate treatment that will cover the most likely
pathogens within a few hours of a patient's initial presen-
tation. Complicating the selection of effective empiric
therapy is the possibility that a patient may ultimately
prove to have a resistant pathogen, an atypical/intracellu-
lar pathogen, or both. The increasing prevalence of drug
resistance among the typical respiratory tract pathogens is
now an important consideration in selecting an antibacte-
rial agent for CAP [2]. High resistance to penicillin (a pre-
viously effective therapy for pneumococcal pneumonia) is
now > 15% in some areas, and an increasing proportion
of S pneumoniae strains are now macrolide-resistant [3,4].
Recognizing the increasing resistance of typical pathogens
and increasing incidence of atypical/intracellular patho-
gens, the American Thoracic Society (ATS) has listed a new
class of agents – the ketolides, which belong to the mac-
rolide-lincosamide-streptograminB (MLSB) family – as a
potential option for oral therapy in CAP [5]. The ketolide
telithromycin has shown good in vitro activity against S
pneumoniae resistant to penicillin and/or macrolides [6],
and potent activity against both typical and atypical/intra-
cellular respiratory tract pathogens [6-17]. In vitro studies
have shown that telithromycin has a low potential to
select for resistant strains and does not induce MLSB resist-
ance [18-20]. A once-daily dose of telithromycin 800 mg
yields drug concentrations in plasma and bronchopulmo-
nary tissues and fluids in excess of the minimum inhibi-
tory concentration (MIC) of most common respiratory
pathogens for 12–24 hours after dosing [21,22]. Concen-
trations of telithromycin in alveolar macrophages, epithe-
lial lining fluid, and bronchial mucosa 8 hours after a
single 800 mg dose exceed those in plasma by factors of
180, 6.5, and 2.2, respectively [21].
The principal objective of the present study was to evalu-
ate the bacteriologic and clinical efficacy and safety of a 7-
day regimen of telithromycin 800 mg once daily in
patients with CAP, with a focus on infections due to pen-
icillin- and/or erythromycin-resistant S pneumoniae.
Methods
Patient sample
Both in-patients and outpatients ≥  13 years of age were
considered for inclusion in the study. The diagnosis of
CAP was based on a new chest x-ray infiltrate and the pres-
ence of ≥  2 of the following: cough; production of puru-
lent sputum; auscultatory findings on pulmonary
examination; dyspnea; fever; elevated white blood cell
count; or a positive Gram stain in a sputum sample. The
decision to admit was based on the clinical judgment of
the patient's physician. Women of childbearing potential
were required to have a negative pregnancy test and use an
accepted method of contraception throughout the study.
Exclusion criteria included: need for parenteral antibacte-
rial therapy; antibacterial therapy for > 24 hours in the
previous 7 days; use of azithromycin, ceftriaxone, or diri-
thromycin within 7 days prior to enrollment; empyema or
lung abscess; pulmonary disease requiring a specific treat-
ment that would make the interpretation of the results dif-
ficult; suspected nonbacterial pathogen; pathogen
resistant to the study medication; known long QTc syn-
drome; sick sinus syndrome; severe hypokalemia; hyper-
sensitivity to macrolides; terminal illness or
immunocompromised status; concomitant medications
known to have a potential interaction with telithromycin;
and impaired hepatic or renal function, or clinically rele-
vant cardiovascular, neurologic, or endocrine disease.
Study design
Patients were enrolled between January and September
2000 at 37 centers in the USA, 10 centers in South Amer-
ica, 6 centers in South Africa, and 5 centers in Canada. The
trial was conducted in accordance with good clinical prac-
tice, and the study protocol and other appropriate study-
related documents were reviewed and approved by the
respective independent ethics committees/institutional
review boards in the participating countries. All patients
provided written informed consent.
The study groups evaluated comprised:
• Safety population: All patients who received ≥  1 dose of
telithromycin and had ≥  1 safety assessment after entry
into the study
• Modified intent to treat (mITT) population: All patients
with a confirmed diagnosis of CAP who received ≥  1 tel-
ithromycin tablet
• Per-protocol clinically evaluable (PPc) population: All
mITT patients who completed the study with no major
protocol violations
• Per-protocol bacteriologically evaluable (PPb) popula-
tion: All clinically evaluable patients who also had a bac-
terial pathogen identified as a causative agent
• Bacteriologic modified intent to treat (bmITT) popula-
tion: All mITT patients with a bacteriologic sample
obtained at pretherapy/entry containing ≥  1 causative
pathogen.
All patients meeting the study inclusion criteria were
assigned to 7 days of open-label treatment with telithro-
mycin 800 mg, administered once daily in the morning as
two 400 mg tablets. Compliance with treatment was
measured by tablet count at the on-therapy visit (Days 3–BMC Infectious Diseases 2005, 5:43 http://www.biomedcentral.com/1471-2334/5/43
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5) and at or before the post-therapy/test of cure (TOC)
visit.
Study endpoints
Bacteriologic outcome in the PPb patients at the post-ther-
apy/TOC visit was the primary efficacy variable. The sec-
ondary efficacy variables in the study were bacteriologic
outcome in the mITT patients who had ≥  1 causative path-
ogen identified at entry (bmITT), and clinical outcome at
the post-therapy/TOC visit in the PPc and mITT patients.
Special attention was given to infections due to S pneumo-
niae resistant to penicillin and/or erythromycin.
Bacteriologic evaluation
Sputum samples were obtained for Gram stain, culture,
and susceptibility analyses at the 4 study visits: prether-
apy/entry (Day 1), on-therapy (Days 3–5), end-of-therapy
(Days 8–10), and post-therapy/TOC (Days 17–24), or at
early withdrawal if applicable. Blood samples for culture
were obtained at pretherapy/entry and at subsequent
assessments if cultures were previously positive, a febrile
state persisted, or no clinical improvement had occurred
after 48 hours of treatment. Susceptibility of pathogens to
telithromycin was tested using disk diffusion and dilution
methods. Susceptibility to macrolides (i.e. erythromycin)
was tested using disk diffusion to establish a minimal
resistance profile to these agents for the pathogens iso-
lated. Oxacillin disks were used to screen for penicillin
resistance among S pneumoniae isolates, and the nitroce-
phin test was used to detect β -lactamase production in H
influenzae and M catarrhalis.
Tests for detection of atypical/intracellular pathogens
included serologic testing of blood samples and/or
polymerase chain reaction (PCR) analysis of oropharyn-
geal swab samples or sputum samples for C pneumoniae
and M pneumoniae, and urine and blood samples for L
pneumophila. Diagnostic criteria for atypical/intracellular
pathogens included negative cultures for common patho-
gens and the following: for L  pneumophila, a 4-fold
increase in paired serum immunoglobulin (Ig) G or IgM
titers, or a positive urinary antigen for L pneumophila sero-
group I; for C pneumoniae, a single IgM titer ≥  1:32 in com-
bination with a positive PCR, or a 4-fold increase in paired
serum IgG/IgM titers; for M pneumoniae, a 4-fold increase
in paired serum IgG or a single IgM titer ≥  1:16 with a pos-
itive PCR test. The tests used to confirm the presence of C
pneumoniae were based upon approved/agreed FDA proce-
dures, including DNA gene probe of the sputum, acute
and convalescent serology for antibodies from the blood,
and microimmunofluorescent antigen testing of sputum.
M pneumoniae tests were based upon acute and convales-
cent serology and DNA gene probe. Convalescent serol-
ogy was not performed on patients initially positive for
common pathogens.
Bacteriologic outcome was based on eradication, pre-
sumed eradication, or persistence of any pathogen iso-
lated in microbiologic cultures at the pretherapy/entry
visit and considered by the investigator to be causative of
CAP. Assessments also included analyses for the presence
of any new pathogen isolated during or after treatment
that was not detected at the pretherapy/entry visit. Bacte-
riologic outcome was categorized as satisfactory if the
causative pathogen was absent in on-therapy or post-ther-
apy cultures (eradication), or if no follow-up culture was
available due to clinical improvement (presumed eradica-
tion). Bacteriologic outcome was considered unsatisfac-
tory if the causative pathogen was still present
(persistence), additional antibacterial therapy was indi-
cated (presumed persistence), a new pathogen emerged
during therapy or within 3 days after treatment was com-
pleted (superinfection), eradication of the causative
organism was followed by replacement with a new species
or serotype of the same organism (reinfection), or the
causative organism reappeared following eradication
(recurrence).
Indeterminate outcomes included cases in which the
patient was withdrawn from the study before follow-up
cultures were obtained, the microbiologic data were
incomplete, concurrent antibacterial treatment was pro-
vided for reasons not associated with CAP or respiratory
tract infections (RTIs), or death occurred that was not due
to CAP or related complications. If ≥  1 causative pathogen
was isolated from the pretreatment culture and the bacte-
riologic outcome was not the same for all pathogens, the
bacteriologic outcome was classified as unsatisfactory.
Clinical evaluation
Patients were evaluated clinically at the four study visits.
At entry (Day 1), patients were screened and evaluated for
infection-related signs and symptoms, with assessment of
vital signs, physical examination, chest x-ray, blood for
hematology and chemistry, and a 12-lead electrocardio-
gram. Similarly, at the on-therapy, end-of-therapy, and
post-therapy/TOC visits, patients were assessed for infec-
tion-related signs and symptoms, with measurement of
vital signs, physical examination and evaluation of overall
clinical status, and blood for hematology and chemistry.
An electrocardiogram recording was repeated at all visits if
the pretherapy/entry QTc was ≥  500 ms or if the subject
was taking a concomitant medication that affected cardiac
conduction. A repeat chest x-ray was obtained at the post-
therapy/TOC visit.
Evaluation of clinical outcome was based on the investi-
gator's assessment of pneumonia-related signs and symp-
toms and a chest x-ray at the post-therapy/TOC visit in
comparison with the pretherapy/entry visit. Possible clin-
ical outcomes were "cure" (returned to preinfection stateBMC Infectious Diseases 2005, 5:43 http://www.biomedcentral.com/1471-2334/5/43
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or postinfectious stigmata indicative of a normal course of
clearance of the infectious process and not requiring fur-
ther antibiotic treatment), "failure" (residual symptoms
or complications of CAP requiring further antibiotic treat-
ment), and "indeterminate" (lost to follow-up or discon-
tinuation not related to study drug).
Safety evaluation
Adverse events (AEs) were spontaneously reported by the
patients and/or observed by the investigator from the time
of entry to 14 days after the final dose of telithromycin.
These events included any sign, symptom, syndrome, or
illness that appeared or worsened and that might impair
patient well-being. Investigators assessed causality of AEs
as being either possibly related or not related to the study
drug. Laboratory safety data analyses (i.e. hematology,
blood chemistry, urinalysis) were performed according to
standard laboratory procedures by Covance Central Labo-
ratory Services, Indianapolis, Indiana.
Statistical analysis
Baseline and outcome data for continuous variables were
calculated using summary statistics, and for categoric var-
iables using frequency tabulation and calculated percent-
ages. Two-sided 95% confidence intervals (CIs) were
calculated for both bacteriologic outcomes and clinical
cure rates. AEs were tabulated, and vital signs and QTc
intervals were calculated with summary statistics. Post-
therapy/TOC clinical laboratory values were compared
with baseline using descriptive statistics, and potentially
important laboratory values were compared with prede-
fined levels outside the extended normal range for the
respective parameter.
Results
A total of 432 in-patients and outpatients ≥  13 years of age
were enrolled at entry and received open-label treatment
with telithromycin; 14 were excluded from the mITT pop-
ulation due to chest x-ray findings that were negative for
pneumonia, resulting in an mITT population of 418
patients. Demographic and clinical characteristics of the
mITT population are summarized in Table 1. Bacteria
other than S pneumoniae identified in bacteremic patients
included Streptococcus viridans and Staphylococcus haemo-
lyticus. During the 7-day treatment period, 395(94.5%)
patients in the mITT population were 100% compliant.
Causative pathogens identified at pretherapy/entry in the
bmITT (n = 255) and PPb populations (n = 149) are
shown in Table 2. Of these, 187/337 (55.5%) isolates in
the bmITT population and 119/204 (58.3%) isolates in
the bacteriologically evaluable group represented three of
the bacteria most commonly implicated in CAP: S pneu-
moniae, H influenzae, and M catarrhalis. Others included
Klebsiella pneumoniae and Staphylococcus aureus. A typical/
intracellular pathogens were detected in a small number
of patients: C pneumoniae,  M pneumoniae, and L pneu-
mophila in 3, 2, and 4 patients, respectively.
Bacteriologic outcome
Satisfactory bacteriologic outcome was achieved in 137/
149 (91.9%, 95% CI: 87.5–96.3) patients in the bacterio-
logically evaluable subgroup and in 215/255 (84.3%,
95% CI: 79.8–88.8) patients in the bmITT subgroup
(Table 3). Results in the bmITT population (a secondary
efficacy variable) thus support the positive outcome
achieved in the bacteriologically evaluable patients. Of
the 12 subjects with an unsatisfactory bacteriologic out-
come, 6 had pathogens considered persistent (H influen-
zae,  S aureus, and Pseudomonas aeruginosa) and 6 had
pathogens classified as presumed persistent (S aureus,
Table 1: Demographic and clinical characteristics for the 
modified intent to treat population.
Characteristic n (%)
Total treated 418
Gender 241 (57.7)
Male 177 (42.3)
Female
Age, years 45.0 [13–92]
Median range
< 65 362 (86.6)
≥  65 56 (13.4)
BMI 417
Mean ± SD 26.9 ± 6.9
Smoking status
Smoker 160 (38.3)
Ex-smoker 79 (18.9)
Nonsmoker 179 (42.8)
Chest x-ray findings
Unilateral 304 (73.6)
Bilateral 109 (26.4)
Single lobe* 351 (85.0)
Multiple lobe 54 (13.1)
Pleural effusion 15 (3.6)
Bacteremia 15 (3.6)
S pneumoniae bacteremia 9 (2.2)
Investigator assessment of current episode
Mild 93 (22.2)
Moderate 279 (66.7)
Severe 46 (11.0)
PSI
Class I 222 (53.1)
Class II 144 (34.4)
Class III 39 (9.3)
Class IV 12 (2.9)
Class V 1 (0.2)
BMI = body mass index; PSI = pneumonia severity index; SD = 
standard deviation.
*"Single lobe" could apply to either unilateral or bilateral lung 
involvement (i.e. 1 lobe per right and/or left lung).BMC Infectious Diseases 2005, 5:43 http://www.biomedcentral.com/1471-2334/5/43
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Enterobacter cloacae, and Enterobacter aerogenes). Clinical
cure was noted in 2 patients with persistent H influenzae
and 2 with persistent P aeruginosa. Eight patients with per-
sistent and presumed persistent bacteria were considered
clinical failures.
Eradication rates, including documented and presumed
eradication, at post-therapy/TOC for the bacteriologically
evaluable and bmITT populations are depicted in Figure
1. Of 204 pathogens identified in bacteriologically
evaluable patients at entry or at subsequent study visits,
189 (92.6%) were eradicated. The eradication rate in the
bmITT population was 284/315(90.2%). It is notable that
all 57 (100%) of the S pneumoniae isolates in the bacteri-
ologically evaluable patients and 70/71 (98.6%) in the
bmITT population were eradicated by telithromycin.
Eradication rates for H influenzae and M catarrhalis were
also high (95.9% and 100%, respectively) in telithromy-
cin bacteriologically evaluable patients.
In vitro susceptibility testing of causative pathogens
revealed that 70/71 S pneumoniae isolates were susceptible
to telithromycin at study entry in the bmITT population,
including those exhibiting resistance to other selected
antibiotics. One isolate had intermediate susceptibility to
telithromycin (MIC 2.00 µg/mL). All M catarrhalis and S
aureus strains isolated in the bacteriologically evaluable
and bmITT populations, and 91.8% and 90.9% of H influ-
enzae  strains isolated in the bacteriologically evaluable
and bmITT populations, respectively, were also suscepti-
ble to telithromycin (MIC ≤  1 µg/mL). It is notable that a
discrepancy was observed between bacteriologic eradica-
tion rates and susceptibility to telithromycin for S aureus
and H influenzae: eradication rates were 80% and 96%,
respectively, and telithromycin susceptibility was 100%
and 90%, respectively, for the two pathogens.
Nine subjects in the per-protocol bacteriologically evalua-
ble population exhibited S pneumoniae strains that were
resistant to penicillin or erythromycin. All of these
patients (including 2 with bacteremia) had bacteriologic
Table 2: Causative pathogens identified at pretherapy/entry in the per-protocol bacteriologically evaluable (PPb) and bacteriologic 
modified intent to treat (bmITT) populations.
Pathogen Number of Isolates in PPb Patients Number of Isolates in bmITT Patients
Total 204 337
S pneumoniae 57 76
H influenzae 49 88
H parainfluenzae 46 81
M catarrhalis 13 23
K pneumoniae 39
S aureus 15 23
Other* 21 37
*Includes: Haemophilus haemolyticus (7); Haemophilus parahaemolyticus (7); Enterobacter cloacae (4); Pseudomonas aeruginosa (4); Acinetobacter 
baumannii (1 bmITT only); Citrobacter freundii (1 bmITT only); Enterobacter aerogenes (1); Enterobacter agglomerans (1 bmITT only); Enterobacter 
amnigenus (1 bmITT only); Enterobacter not otherwise specified (NOS) (1 bmITT only); Neisseria meningitides (1); Proteus mirabilis (1); Proteus NOS (1 
bmITT only); Streptococcus, viridansgroup(5); Staphylococcus haemolyticus (1).
Table 3: Bacteriologic outcomes at the post-therapy/test of cure evaluation for the bacteriologically evaluable and bacteriologic 
modified intent to treat (bmITT) populations.
Bacteriologically Evaluable Population bmITT Population
Assessment n (%) 95% CI* n (%) 95% CI*
n1 4 9 2 5 5
Satisfactory† 137 (91.9) 87.5; 96.3 215 (84.3) 79.8; 88.8
Unsatisfactory‡ 12 (8.1) 40 (15.7)
Indeterminate - 16 (6.3)
*Two-sided 95% confidence interval (CI).
†Includes eradication, presumed eradication, and colonization.
‡Includes reinfection, superinfection, recurrence, presumed persistence, and persistence.BMC Infectious Diseases 2005, 5:43 http://www.biomedcentral.com/1471-2334/5/43
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Bacteriologic eradication rates by causative pathogen in the bacteriologically evaluable (PPb) and the bacteriologic modified  intent to treat (bmITT) populations at the post-therapy/test of cure (TOC) visit Figure 1
Bacteriologic eradication rates by causative pathogen in the bacteriologically evaluable (PPb) and the bacteriologic modified 
intent to treat (bmITT) populations at the post-therapy/test of cure (TOC) visit.
Table 4: Bacteriologic and clinical outcome in per-protocol bacteriologically evaluable patients with S pneumoniae isolates resistant to 
penicillin G (Pen G) and/or erythromycin A (Ery A).
MIC Susceptibility* (µg/mL)
Subject No. Isolate (Source) TEL Pen G Ery A Bacteriologic Outcome† Clinical Outcome
Subjects with single-pathogen S pneumoniae isolate
1 S pneumoniae (sputum) 0.030 (S) 0.030 (S) b>8.000 (R) Eradication Cure
2 S pneumoniae (sputum) 0.030 (S) 2.000 (R) 0.250 (S) Presumed eradication Cure
3 S pneumoniae (sputum) 0.500 (S) 2.000 (R) 8.000 (R) Presumed eradication Cure
Subjects with multiple-pathogen S pneumoniae isolate
4 S pneumoniae (sputum) 0.060 (S) 2.000 (R) 4.000 (R) Presumed eradication Cure
M catarrhalis 0.120 (S) ND 0.120 Presumed eradication Cure
5 S pneumoniae (sputum) 0.250 (S) 2.000 (R) 8.000 (R) Presumed eradication Cure
6 S pneumoniae (sputum) 0.030 (S) 2.000 (R) 0.060 (S) Presumed eradication Cure
H influenzae 0.002 (S) ND 1.000 Presumed eradication Cure
M catarrhalis 0.120 (S) ND 0.250 Presumed eradication Cure
7 S pneumoniae (sputum) 0.500 (S) 2.000 (R) 8.000 (R) Presumed eradication Cure
H influenzae 2.000 (S) ND 4.000 Presumed eradication Cure
8 S pneumoniae (blood) 1.000 (S) 0.250 (I) 8.000 (R) Presumed eradication Cure
H influenzae 1.000 (S) ND 4.000 Presumed eradication Cure
9 S pneumoniae (blood) 1.000 (S) 0.500 (I) 8.000 (R) Presumed eradication Cure
H influenzae 8.000 (R) ND 4.000 Presumed eradication Cure
S aureus 0.120 (S) ND 0.500 Presumed eradication Cure
MIC = minimum inhibitory concentration; ND = no data; TEL = telithromycin.
*Susceptibility: S = sensitive; I = intermediate; R = resistant.
†Bacteriologic outcome.
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outcomes of eradication or presumed eradication and
clinical outcomes of cure (Table 4).
In the bmITT population subgroup, penicillin resistance
(MIC  ≥  2.0 µg/mL), penicillin intermediate resistance
(MIC = 0.12–1.0 µg/mL), and erythromycin (macrolide)
resistance (MIC ≥  1.0 µg/mL) were noted in 8/71 (11.3%),
4/71 (5.6%), and 9/71 (12.7%) S pneumoniae strains,
respectively. Of those strains showing resistance to peni-
cillin, 5/8 (62.5%) were also resistant to the macrolides
and all 8 (100%) were resistant to trimethoprim/sulfame-
thoxazole and cefuroxime axetil. Seven of the macrolide-
resistant strains (77.8%) were also resistant to trimetho-
prim/sulfamethoxazole, and 5 (55.6%) were resistant to
cefuroxime axetil based on approved National Committee
for Clinical Laboratory Standards susceptibility testing
breakpoints.
Clinical outcome
Clinical cure with telithromycin in the PPc population at
the post-therapy/TOC visit was achieved in 332/357
(93.0%) patients overall (Table 5). Clinical cure in the
mITT population at the post-therapy/TOC visit was 357/
418 (85.4%), reinforcing the clinical outcome achieved
by telithromycin in the clinically evaluable patients.
No patient with a satisfactory bacteriologic outcome had
a clinical failure. Clinical cure was achieved for 100% of
patients infected with S pneumoniae, H influenzae, and M
catarrhalis. Telithromycin also had excellent activity in
clinically evaluable patients infected with atypical/intrac-
ellular pathogens. Clinical cure was achieved in 100% of
patients infected with C pneumoniae (n = 3), M pneumoniae
(n = 2), and L pneumophila (n = 4).
Telithromycin was highly effective in patients with risk
factors for increased morbidity. In clinically evaluable
patients with bacteremia (n = 14), in addition to those
with S pneumoniae bacteremia (n = 9), telithromycin treat-
ment yielded a clinical cure rate of 100%. In clinically
evaluable patients ≥  65 years of age (n = 47), the clinical
outcome was 95.7% (45/47 cured). Patients with multiple
lobe involvement had a clinical cure rate of 90.5% (38/42
cured) and those with pneumonia severity index (PSI)
scores of III (n = 35) and IV (n = 9) had clinical cure rates
of 91.4% and 100%, respectively.
Safety evaluation
Of 430 patients who received ≥  1 dose of study medica-
tion and who were evaluated for safety, 154 (35.8%) expe-
rienced ≥  1 treatment-emergent adverse event (TEAE) and
87 (20.2%) experienced AEs considered by the investiga-
tor to be treatment-related. (All AEs classified as treat-
ment-emergent and possibly treatment-emergent were
considered to be treatment-emergent.) Most TEAEs,
regardless of causality, were considered by the investiga-
tors to be mild or moderate in severity. The two most
commonly reported TEAEs were diarrhea in 35 patients
(8.1%) and nausea in 25 patients (5.8%).
One or more serious AEs occurred in 12 patients (2.8%)
and were considered unrelated to the study drug by the
investigators. Clinically noteworthy abnormal laboratory
values (CNALVs) occurred in 102 of the 430 patients in
the safety evaluation. The most common CNALVs were
decreased creatinine clearance reported in 63 patients
(14.7%), increased aspartate aminotransferase (AST) con-
centration in 16 patients (3.7%), increased alanine ami-
notransferase (ALT) concentration in 15 patients (3.5%),
increased alkaline phosphatase concentration in 12
patients (2.8%), and increased potassium concentration
in 12 patients (2.8%). Most of these CNALVs were present
at study entry (61.9%). Furthermore, 55% of all CNALVs
did not deteriorate further during the treatment period, or
laboratory values returned to within the normal range at
the final post-therapy laboratory assessment. One case of
decreased creatinine clearance resulting in renal insuffi-
ciency noted on Day 1 was considered moderate in inten-
sity by the investigator and not related to the study drug.
There were no cases of clinical hepatitis reported during
the study.
AEs resulting in discontinuation of telithromycin
occurred in 11 patients (2.6%). Six patients who discon-
tinued treatment experienced allergic reaction, abdominal
Table 5: Clinical outcomes for patients according to 
demographic characteristics of interest (clinically evaluable 
population at the post-therapy/test of cure visit)
Clinical Outcome
Subgroup n Clinical cure, n (%)
All patients 357 332 (93.0)
Bacteremia 14 14 (100)
S pneumoniae bacteremia 99  ( 1 0 0 )
Age ≥  65 years 47 45 (95.7)
Chest x-ray findings
Unilateral 256 236 (92.2)
Bilateral 97 92 (94.8)
Single lobe* 303 282 (93.1)
Multiple lobes 42 38 (90.5)
Fever >38°C (oral or equivalent) 123 117 (95.1)
PSI
Class I 187 176 (94.1)
Class II 126 115 (91.3)
Class III 35 32 (91.4)
Class IV 9 9 (100)
PSI = pneumonia severity index.
*"Single lobe" could apply to either unilateral or bilateral lung 
involvement (i.e. 1 lobe per right and/or left lung).BMC Infectious Diseases 2005, 5:43 http://www.biomedcentral.com/1471-2334/5/43
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pain, diarrhea, vomiting, vertigo, or increased ALT
concentration, which were considered possibly related to
telithromycin. The remaining events leading to
discontinuation (considered unrelated to telithromycin)
were confusion, apnea, lung disorder, respiratory disor-
der, and myocardial infarction. Two deaths occurred dur-
ing the study (1 resulting from myocardial infarction and
1 due to renal insufficiency and acute aspiration). Neither
death was considered related to telithromycin. There were
no clinically significant changes in vital signs from base-
line mean or median values. Two patients experienced
increases of ≥  60 ms in QTc intervals, but these were not
associated with any AEs and were not considered clini-
cally significant.
Discussion
Results of this study demonstrate that 7-day treatment
with telithromycin 800 mg once-daily telithromycin, the
first ketolide antibacterial to undergo clinical develop-
ment, is safe and effective in the treatment of CAP. Tel-
ithromycin was well tolerated and effective in > 90% of
clinically and bacteriologically evaluable patients treated
according to the study protocol. The favorable results for
telithromycin in the present study are consistent with
those reported previously in comparative trials. The safety
and efficacy of telithromycin 800 mg once daily for vary-
ing treatment durations have been compared with those
of clarithromycin, amoxicillin, and trovafloxacin. Respec-
tive clinical cure rates for 5-day and 7-day telithromycin
versus 10-day clarithromycin were 89.3% and 88.8% ver-
sus 91.8%; for 10-day telithromycin versus 10-day amox-
icillin, 94.6% versus 90.1%; and for 7- to 10-day
telithromycin versus 7- to 10-day trovafloxacin, 90.0%
versus 94.2% [23-25]. While the optimal treatment dura-
tion for CAP has not yet been established, 7-day telithro-
mycin treatment appears to be effective. This shorter,
once-daily regimen may encourage patients to complete
their prescribed course of medication.
An important consideration in antibacterial treatment of
patients with CAP is efficacy in those at increased risk of
morbidity. Of particular concern is the possibility of bac-
teremic infection when it may not be suspected (a situa-
tion in which treatment with standard antibiotics could
fail). Musher et al [26] have demonstrated that similar
proportions of bacteremic cases occur in patients with
pneumococcal CAP regardless of disease severity (i.e.
among those with PSI scores ranging from I to IV). Tel-
ithromycin was highly effective in clinically evaluable
patients with bacteremia, including S pneumoniae bactere-
mia. In addition, the clinical outcome in this study in
patients ≥  65 years of age was 95.7% (45/47 cured); in
those with PSI scores of III and IV, telithromycin resulted
in clinical cure rates of 91.4% and 100%, respectively. In
other comparative studies, telithromycin showed compa-
rable or slightly superior efficacy in high-risk patients ver-
sus clarithromycin and amoxicillin [23-25].
Telithromycin demonstrated bacteriologic eradication
rates of 100% for S pneumoniae (57/57 isolates) in the bac-
teriologically evaluable patient population, including all
9 S pneumoniae strains demonstrating resistance to peni-
cillin and/or erythromycin. Telithromycin was also 100%
effective against M catarrhalis (13/13 isolates eradicated)
and 96% effective against H influenzae (47/49 isolates
eradicated). Susceptibility testing performed in this study
revealed that penicillin- and macrolide (erythromycin)-
resistant S pneumoniae strains showed resistance to clari-
thromycin, trimethoprim/sulfamethoxazole, and cefurox-
ime axetil: all 8 strains of penicillin-resistant S pneumoniae
were resistant to both trimethoprim/sulfamethoxazole
and cefuroxime axetil, and 5 (62.5%) were resistant to
clarithromycin. Seven of the erythromycin-resistant
strains (77.8%) were also resistant to trimethoprim/sul-
famethoxazole, and 5 (55.6%) were also resistant to
cefuroxime axetil.
The number of atypical/intracellular pathogens isolated
from CAP patients in this study was small – in part due to
the study design, which did not obtain convalescent
serum in patients with initial cultures positive for typical
pathogens and excluded patients with cultures positive for
typical pathogens from the final analysis of atypical/intra-
cellular pathogens. All cases (3 patients with C pneumo-
niae, 2 with M pneumoniae, and 4 with L pneumophila) were
clinically cured.
The safety profile for telithromycin in this study was sim-
ilar to that reported in a review of previous clinical trials
of this ketolide [7]. Telithromycin was very well tolerated,
with the most commonly reported AEs (generally involv-
ing the gastrointestinal system [diarrhea and nausea])
being mild to moderate. Study discontinuations occurred
in only 6/430 (1.4%) patients due to AEs considered by
the investigators to be possibly related to the study drug.
In summary, 7 days of once-daily treatment with telithro-
mycin 800 mg orally was effective and well tolerated in
adolescent and adult patients with CAP, including those
infected with resistant strains of S pneumoniae. Telithro-
mycin may be considered a convenient, well tolerated,
and effective treatment option for CAP in this era of
increasing antibacterial resistance.
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